biote (BTMD) Competitors $5.91 -0.08 (-1.34%) (As of 05:26 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends BTMD vs. NTLA, ARVN, SYRE, CALT, GYRE, ANIP, SNDX, ARDX, SPRY, and BCAXShould you be buying biote stock or one of its competitors? The main competitors of biote include Intellia Therapeutics (NTLA), Arvinas (ARVN), Spyre Therapeutics (SYRE), Calliditas Therapeutics AB (publ) (CALT), Gyre Therapeutics (GYRE), ANI Pharmaceuticals (ANIP), Syndax Pharmaceuticals (SNDX), Ardelyx (ARDX), ARS Pharmaceuticals (SPRY), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry. biote vs. Intellia Therapeutics Arvinas Spyre Therapeutics Calliditas Therapeutics AB (publ) Gyre Therapeutics ANI Pharmaceuticals Syndax Pharmaceuticals Ardelyx ARS Pharmaceuticals Bicara Therapeutics Intellia Therapeutics (NASDAQ:NTLA) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Which has preferable valuation and earnings, NTLA or BTMD? biote has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$43.09M26.97-$481.19M-$5.44-2.10biote$193.06M1.66$3.32M$0.2622.73 Is NTLA or BTMD more profitable? biote has a net margin of 5.20% compared to Intellia Therapeutics' net margin of 0.00%. biote's return on equity of -32.41% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia TherapeuticsN/A -49.34% -40.27% biote 5.20%-32.41%22.26% Does the MarketBeat Community favor NTLA or BTMD? Intellia Therapeutics received 421 more outperform votes than biote when rated by MarketBeat users. However, 100.00% of users gave biote an outperform vote while only 69.27% of users gave Intellia Therapeutics an outperform vote. CompanyUnderperformOutperformIntellia TherapeuticsOutperform Votes43569.27% Underperform Votes19330.73% bioteOutperform Votes14100.00% Underperform VotesNo Votes Do insiders & institutionals believe in NTLA or BTMD? 88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 3.2% of Intellia Therapeutics shares are held by company insiders. Comparatively, 13.9% of biote shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer NTLA or BTMD? In the previous week, Intellia Therapeutics had 2 more articles in the media than biote. MarketBeat recorded 6 mentions for Intellia Therapeutics and 4 mentions for biote. biote's average media sentiment score of 0.92 beat Intellia Therapeutics' score of 0.68 indicating that biote is being referred to more favorably in the news media. Company Overall Sentiment Intellia Therapeutics Positive biote Positive Do analysts recommend NTLA or BTMD? Intellia Therapeutics presently has a consensus target price of $54.94, indicating a potential upside of 381.49%. biote has a consensus target price of $9.11, indicating a potential upside of 54.15%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than biote.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 0 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.72biote 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, NTLA or BTMD? Intellia Therapeutics has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, biote has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Summarybiote beats Intellia Therapeutics on 11 of the 19 factors compared between the two stocks. Ad StocksToTradeTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’s promise, and a secret Elon project set to revolutionize a $23 Trillion market…Click here to review Tim’s special Holiday offer before it’s too late. Get biote News Delivered to You Automatically Sign up to receive the latest news and ratings for BTMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTMD vs. The Competition Export to ExcelMetricbioteMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$321.13M$1.14B$5.15B$9.02BDividend YieldN/AN/A4.96%4.20%P/E Ratio22.7330.9486.6217.07Price / Sales1.665.721,126.05116.50Price / Cash13.4010.6643.2737.84Price / Book-10.191.904.824.96Net Income$3.32M-$50.37M$120.07M$225.17M7 Day Performance2.07%0.08%1.23%4.45%1 Month Performance-10.59%-9.20%16.54%3.07%1 Year Performance19.64%-6.98%28.85%17.61% biote Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTMDbiote2.8029 of 5 stars$5.91-1.3%$9.11+54.1%+21.3%$321.13M$193.06M22.73194Short Interest ↑NTLAIntellia Therapeutics4.3969 of 5 stars$12.03-1.2%$54.94+356.7%-60.7%$1.23B$43.09M-2.21600ARVNArvinas2.5485 of 5 stars$17.83-3.5%$63.50+256.1%-53.8%$1.23B$161.10M-3.82445Short Interest ↑SYRESpyre Therapeutics1.9425 of 5 stars$23.34-2.2%$51.50+120.7%+10.0%$1.20B$890,000.00-3.12100CALTCalliditas Therapeutics AB (publ)0.0687 of 5 stars$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180GYREGyre Therapeutics0.3002 of 5 stars$12.45+11.8%N/A-51.5%$1.16B$105.03M0.0040Short Interest ↑Gap UpANIPANI Pharmaceuticals4.6871 of 5 stars$54.00+1.2%$77.71+43.9%-1.3%$1.14B$555.46M-98.18642Short Interest ↑News CoveragePositive NewsSNDXSyndax Pharmaceuticals3.9609 of 5 stars$13.09+0.1%$36.90+181.9%-40.9%$1.12B$16M-3.61110High Trading VolumeARDXArdelyx4.2589 of 5 stars$4.64-3.7%$10.42+124.5%-16.0%$1.10B$251.85M-15.47267Positive NewsGap DownSPRYARS Pharmaceuticals3.6672 of 5 stars$10.98-1.8%$24.00+118.6%+96.9%$1.07B$2.57M-21.5390BCAXBicara TherapeuticsN/A$19.27+9.6%$43.00+123.1%N/A$1.05BN/A0.0032 Related Companies and Tools Related Companies Intellia Therapeutics Alternatives Arvinas Alternatives Spyre Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Gyre Therapeutics Alternatives ANI Pharmaceuticals Alternatives Syndax Pharmaceuticals Alternatives Ardelyx Alternatives ARS Pharmaceuticals Alternatives Bicara Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BTMD) was last updated on 12/30/2024 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
